Stem cell transplantation is a treatment that is used mainly for various forms of blood cancers. The sick or injured blood stem cells are replaced by healthy donor stem cells to extend the lives of patients suffering from leukaemia. Sometimes, due to this treatment, the life-threatening disease can even be overcome. To monitor success of stem cell transplantation and transplant engraftment, molecular methods are deployed, which measure the ratio between healthy donor and patients leukemic cells.
This measurement was so far accomplished with semi-quantitative methods that could determine the respective ratio only up to about 2-5 % accuracy. In contrast, analyses now can exactly succeed 0.05 %. The choice of used technologies ensures high sensitivity and hence the predictive value of the diagnosis. As a result, threatening relapse following stem cell transplantation, which is by means a highly stressful and risky treatment for patients, can be recognized earlier, and, might even be prevented.
About Biotype diagnostic:
Biotype Diagnostic GmbH develops molecular in-vitro diagnostics (IVD) for medical areas such as haematology/oncology and dermatology. The company thereby draws back on many years of experience in the development and production of test systems in the DNA analysis. In close collaboration with academic and clinical partners Biotype continuously transfer scientific know-how into marketable applications to create holistic diagnostics. Recently, the company’s portfolio was extended by DNA-extraction systems, which allow sample preparation of diverse biological liquids and tissues.
Press Release Distribution with Free Press Release Website Service
